Evaluation and Outcome of Para-pneumonic Effusion

NCT03480490 | Unknown

• 1 other identifier: EOPE
• Study Type: observational
• Target: 25
• Locations: 0 countries
• Sites: N/A

Brief Summary

Pleural effusion is the accumulation of excess fluid in the pleural cavity, which results in disturbance of the equilibrium between vascular hydrostatic and oncotic pressures. The underlying causes of pleural effusion include pleural inflammation or infection, congestive heart failure, lymphatic drainage blockage and malignancy.A parapneumonic effusion is a pleural effusion associated with lung infection. Early in the course of parapneumonic effusion, the pleura becomes inflamed with leakage of cellular elements, protein, and fluid into the pleural space, forming the effusion. Subsequent bacterial invasion results in a frank empyema, the presence of which often requires thoracentesis.

Conditions

Pleural Effusion

Outcome Measures

Primary Outcomes (1)

• cure rate from effusion

  to evaluate the cure rate from para-pneumonic effusion among children

  baseline

Interventions

Pleural fluid C-reactive protein DIAGNOSTIC_TEST

C-reactive protein is an acute phase protein that is synthesized by the liver in response to various stimuli. The pleural fluid c-reactive protein levels are likely to reflect the serum levels because the presence of c-reactive protein in the pleural fluid may be due to increased diffusion from the blood as a result of inflamed capillary leakage. Pleural c-reactive protein has been proposed as a specific biomarker for the differential diagnosis of pleural effusions and reportedly exhibits higher sensitivity and specificity than serum c-reactive protein. c-reactive protein can be considered a good candidate due to its 1000-fold elevation in response to infection and the positive correlation between the serum and pleural c-reactive protein levels. Pleural fluid c-reactive protein level was significantly higher in exudates than that in transudative effusion.

Eligibility Criteria

• Age: 1 Month - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

This study was conducted on patients with para-pneumonic effusion who were admitted to the Assiut University Pediatrics Hospital in the period between january 2019 and january 2020.

You may qualify if:

• This study will be conducted upon patients(male and females),from 1 month to 18 years with para-pneumonic effusion at assuit university pediatric hospital from January to june 2019 after taking consents.

You may not qualify if:

• age: \>18 years old congenital heart disease lymphatic drainage blockage post traumatic pleural effusion renal diseases hepatic diseases neoplastic diseases

Sponsors & Collaborators

• Assiut University: lead

Related Publications (1)

• Adeoye PO, Johnson WR, Desalu OO, Ofoegbu CP, Fawibe AE, Salami AK, Fadeyi A, Akin-Dosumu AA, Rasheedat IM; Ilorin Pleural Effusion Study Group. Etiology, clinical characteristics, and management of pleural effusion in Ilorin, Nigeria. Niger Med J. 2017 Mar-Apr;58(2):76-80. doi: 10.4103/0300-1652.219349.

  PMID: 29269986 BACKGROUND

MeSH Terms

Conditions

Pleural Effusion

Condition Hierarchy (Ancestors)

Pleural Diseases; Respiratory Tract Diseases

Study Officials

• Yasser F Abdel-raheim, PhD

  Assiut University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Walaa R Ahmed, MD

CONTACT

01015226240; walaarashad226240@gmail.com

Moustafa M El-Saied, PhD

CONTACT

01060779253; moustafa13@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle investigator

Study Record Dates

• First Submitted: March 19, 2018
• First Posted: March 29, 2018
• Study Start: January 1, 2019
• Primary Completion: January 1, 2020
• Study Completion: May 1, 2020
• Last Updated: March 29, 2018

Record last verified: 2018-03